Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

XellSmart Raises $27.6 Million for Low-Cost Stem Cell Therapies

publication date: Nov 8, 2022

Shanghai XellSmart Biomedical closed a $27.6 million in Series A1 financing to develop low-cost stem cell therapies for major unmet needs including Parkinson's disease. Founded in 2021, XellSmart has a 1,400-square-meter Shanghai R&D center and a 3,400-square-meter pilot production base in Suzhou under construction. Besides Parkingson’s, the company is developing stem cell therapies for retinopathy, brain trauma and cancer. The round was co-led by Qiming Venture, Lilly Asia Ventures, FIG and CSSD. Qiming and Lilly are previous investors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here